

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/006692 A1

(51) International Patent Classification⁷: A23L 1/29, (74) Agents: HALL, Marina et al.; Reckitt Benckiser plc, 1/308, A61K 9/14 Group Patents Department, Dansom Lane, Hull HU8 7DS (GB).

(21) International Application Number: PCT/GB2003/003040

(22) International Filing Date: 11 July 2003 (11.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0216147.9 12 July 2002 (12.07.2002) GB

(71) Applicant (for all designated States except US): RECKITT BENCKISER HEALTHCARE (UK) LIMITED [GB/GB]; 103-105 Bath Road, Slough, Berkshire SL1 3UH (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DETTMAR, Peter, William [GB/GB]; Tithe House, Tithe Barn Lane, Patrington, East Yorkshire HU12 0PE (GB). HAVLER, Michael, Edward [GB/GB]; Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull HU8 7DS (GB). MCKIE, Kevin [GB/GB]; 33 Northolme Road, Hessle, East Yorkshire HU13 9HR (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/006692 A1

(54) Title: IMPROVED BULKING AGENT COMPOSITIONS

(57) Abstract: The present invention provides an ingestible composition comprising a fibre or saccharide bulking agent, an ingestible silica, and an ingestible surfactant. The provision of the silica and the surfactant provides a synergistic benefit in the dispersal of the bulking agent in water thus making it easier and/or quicker to obtain an imbibable liquid. The bulking agent may be ispaghula, a natural material of benefit in promoting good bowel function.

IMPROVED BULKING AGENT COMPOSITION

The present invention relates to medicinal compositions comprising fibre or saccharide bulking agents.

5 Ingestible fibre- or saccharide-containing compositions for the relief of gastric and digestive dysfunctions are known. Examples of such compositions include granular psyllium husk fibre (ispaghula) intended to be stirred in
10 measured amounts into a volume of liquid, usually water or soft drinks. After stirring, the drinking composition is intended to be quickly imbibed due to the propensity of the ispaghula to absorb water readily and swell to form a
15 viscous gel-like mass. It is the property of water absorption which has the desired characteristic of fibre or saccharide-containing ingestible compositions for gastric and digestive dysfunctions. Once the fibre or
20 saccharide-containing composition has absorbed water to produce the gel-like mass, the mass is relatively insoluble and fibrous, and is transported through the gut quickly with minimal digestion, helping to alleviate constipation and other digestive dysfunctions.

Other forms, such as capsules forms for ingestion, are
25 also available, such capsules being designed to be broken down in the gut, wherein the released fibre or saccharide bulking agent absorbs water from the gut to form the viscous mass.

30 However, for beneficial ease-of-use properties, a particulate form is particularly advantageous to the end user, as this can be stirred into a volume of liquid, for a more pleasant taste, and the granular form of the fibre

or saccharide absorbs water from the gut more quickly than a capsule form. However, there are a number of problems involved in using a granular form of the fibre- or saccharide-containing ingestible compositions.

5

Primarily, it is desirable for the ingestible compositions to disperse easily in liquid, for the user's convenience and/or so that the resultant drink is more palatable and/or easier to swallow. Any new composition must be as 10 good as or, preferably, better than, existing compositions in this respect.

Secondly, the handling of some ingestible fibre- or saccharide-containing compositions is not straightforward. 15 For example in commercial production ispaghula is milled then isopropyl alcohol and a granulating agent polyvinyl pyrrolidone are added. These steps aid handling of the compositions during manufacturing, before the isopropyl alcohol is removed prior to packaging the product for 20 sale. The granulation also aids the dispersion of the ispaghula into a volume of liquid, prior to ingestion. However, the use of the granulating agent and isopropyl alcohol increases the cost of production and the use of 25 the isopropyl alcohol is undesirable from an environmental and a health and safety perspective.

Thus, from the foregoing, it is apparent that there is a need for the provision of an ingestible composition which comprises a fibre or saccharide bulking agent, in which 30 the ingestible composition disperses easily in an aqueous liquid and/or is of improved manufacture.

It has now been determined that an ingestible composition comprising a fibre or saccharide bulking agent, which also includes an ingestible silica in conjunction with an ingestible surfactant, can offer benefit in the manufacture of the ingestible composition, and can increase the rate at which the ingestible composition disperses in water or other ingestible liquid.

Therefore, according to the present invention there is provided an ingestible composition comprising a fibre or saccharide bulking agent, an ingestible silica and an ingestible surfactant wherein said composition is in a form so that in use it is dispersed in a liquid prior to ingestion.

According to a second aspect of the invention there is provided an ingestible composition comprising a fibre bulking agent selected from ispaghula or a bran, an ingestible silica, and an ingestible surfactant.

The presence of both an ingestible silica and an ingestible surfactant can confer significant, eg synergistic, benefits. For example when the fibre or saccharide bulking agent is ispaghula the ternary composition has outstanding wettability properties, and is easy to manufacture, for example by simple blending.

Suitably the fibre or saccharide bulking agent is a natural ingestible fibre (by which term we include herein fibre extracts). Plant-derived fibre bulking agents are preferred, such as cellulose or derivatives thereof; psyllium husk fibre (ispaghula); or brans such as corn, oat, wheat or rice brans. Animal-derived fibre, fruit-

derived fibre and/or synthetic ingestible fibres may also be used. Examples include barley fibre, pea fibre, sugar beet fibre and β -glucan.

5 Particularly preferred as a fibre bulking agent is ispaghula.

The ispaghula may comprise whole ispaghula seeds, but preferably at least part of the ispaghula comprises 10 separated ispaghula seed husks. More preferably the ispaghula comprises at least 50% wt separated ispaghula husks, most preferably at least 95% wt separated ispaghula husks. Suitably the remainder of the ispaghula comprises other seed parts and/or other ispaghula plant materials. 15 In preferred compositions the seed kernels themselves have been substantially removed to leave the husks.

If the bulking agent is a saccharide-containing bulking agent it is suitably a polysaccharide, an arabinoxylan, a 20 galactomannan, a glucomannan, preferably an algin, especially alginic acid or a salt derivative thereof, such as calcium alginate, magnesium alginate, sodium alginate or potassium alginate.

25 Algins may be found in and isolated from various organisms, in particular from algae belonging to the order *Phaeophyceae* and soil bacteria such as *Azotobacter vinelandii* and *Azotobacter crococcum* and from several strains of *Pseudomonas* bacteria. Common algal sources of 30 algins include *Laminaria digitata*, *Ecklonia maxima*, *Macrocystis pyrifera*, *Lessonia nigrescens*, *Ascophyllum nodosum*, *Laminaria japonica*, *Durvillea antartica*, *Durvillea potatorum* and, especially, *Laminaria hyperborea*.

Alginic acid is a linear hetero-polysaccharide comprising units of β -D-mannuronic acid and α -L-guluronic acid. Alginic acid may comprise homopolymeric sequences of 5 mannuronic acid, homopolymeric sequences of guluronic acid, and mixed sequences of mannuronic acid and guluronic acid units.

Salts of alginic acid used may include alkali metal salts, 10 for example sodium and potassium salts, and ammonium and alkanolamine salts. Alkali metal salts are of particular interest.

The term "algins" as used herein includes alginic acid and 15 salts of alginic acid, irrespective of the relative proportion of mannuronic and guluronic units, and is intended to include glycolated or alkoxylated derivatives, especially those derivatised with propylene glycol. However, preferred compounds are not alkoxylated or 20 glycolated.

Suitably the fibre or saccharide bulking agent is present in the ingestible composition in an amount of at least 10wt%, preferably at least 30wt%, and most preferably at 25 least 40wt% of the total weight of the ingestible composition.

Suitably the fibre or saccharide bulking agent is present in the ingestible composition in an amount up to 90wt%, 30 preferably up to 80wt%, and most preferably up to 75wt% of the total weight of the ingestible composition.

Suitably the silica is fumed or precipitated synthetic or natural silica. The silica may be amorphous or crystalline.

5 Suitably the mean particle size of the silica is at least 5nm, preferably at least 10nm.

10 Suitably the mean particle size of the silica is up to 5 μ m, preferably up to 0.75 μ m, more preferably up to 0.5 μ m, and most preferably up to 0.2 μ m.

15 The silica material that is used may typically contain 0.1 to 2.5wt% alumina (Al_2O_3), preferably 0.5 to 2wt% alumina, and most preferably about 1wt% alumina, based on the weight of the silica.

20 One suitable silica material is Syloid 244 which is amorphous silica, has a mean particle size of about 3 μ m and is provided by W R Grace & Co. Another suitable silica materials is Silox 15, also from W R Grace & Co., and which has a mean particle size of about 4 μ m.

25 Another suitable silica material is Huber Zep 49 which is amorphous silica from J M Huber Corporation and contains about 1 wt% alumina.

Another suitable silica is Aerosil 200 from Degussa Company. It contains less than 0.05 wt% alumina and has a mean particle size of 12 nm.

Preferably the silica is colloidal silica, and a preferred silica is a colloidal silica which is sold under the trade mark CAB-O-SIL, by Cabot Inc, USA.

5 Suitably the specific surface area of the silica is at least $50\text{m}^2\text{ g}^{-1}$, preferably at least $150\text{m}^2\text{ g}^{-1}$.

Suitably the specific surface area of the silica is up to $400\text{m}^2\text{ g}^{-1}$, preferably up to $300\text{m}^2\text{ g}^{-1}$ most preferably up to 10 $200\text{m}^2\text{ g}^{-1}$.

Suitably the silica is present in the ingestible composition in an amount at least 0.01wt%, preferably at least 0.05wt%, more preferably at least 0.1wt% and most preferably at least 0.25wt%, of the total weight of the ingestible composition.

The upper limit of silica in the ingestible composition may be up to 11 wt%. Suitably the silica may be present in the ingestible composition in an amount up to 5wt%, preferably up to 2wt%, more preferably up to 1wt%, and most preferably up to 0.6wt%, of the total weight of the ingestible composition.

25 Preferably the ingestible surfactant is a polyethylene-, polypropylene-, or polyoxyethylene-based surfactant. Suitable polyethylene or polyoxyethylene-based surfactants include polyethylene glycols and polyoxyethylene sorbitan fatty acid esters (polysorbates).

30 Suitable polyethylene glycols have a molecular weight of between 200 and 40,000, preferably between 200 and 1,000, and more preferably between 200 and 600. Suitable

polyethylene glycols include MACROGOLD and MACROGOLUM polyethylene glycols sold by ICI Surfactants, UK. Other suitable surfactants include polyoxyethylene monostearates and glycerol polyethylene glycol oxystearates.

5

Suitably the surfactant is present in the ingestible composition in an amount at least 0.01wt%, preferably at least 0.05wt%, more preferably at least 0.1wt%, and most preferably at least 0.2wt%, of the total weight of the 10 ingestible composition.

Suitably the surfactant is present in the ingestible composition in an amount up to 5wt%, preferably up to 3wt%, more preferably up to 2wt% and most preferably up to 15 1wt%, of the total weight of the ingestible composition.

When the surfactant is polyethylene glycol it is preferably present in an amount at least 0.1wt%, more preferably at least 0.3wt%, of the total weight of the 20 ingestible composition.

When the surfactant is polyethylene glycol it is preferably present in an amount up to 2wt%, more preferably up to 1.5wt%, of the total weight of the 25 ingestible composition.

When the surfactant is a polyoxyethylene sorbitan fatty acid ester it is preferably present in an amount at least 0.01wt%, more preferably at least 0.05wt%, and most 30 preferably at least 0.08wt%, of the total weight of the ingestible composition.

When the surfactant is a polyoxyethylene sorbitan fatty acid ester it is preferably present in an amount up to 2wt%, more preferably up to 1wt%, and most preferably up to 0.5wt%, of the total weight of the ingestible
5 composition.

The percentages stated represent the total complement of the silica and surfactant, that is, summated if there is more than one silica or surfactant in the composition.

10 The ingestible composition may further comprise ingestible co-ingredients such as a bicarbonate for example sodium bicarbonate, an ingestible acid, for example citric acid, a flavouring, or a colouring, for example.

15 Preferably the ingestible composition does not contain a granulating agent.

20 Most preferably the ingestible composition does not contain polyvinyl pyrrolidone.

Preferably the ingestible composition does not contain any residue of polyvinyl alcohol.

25 The composition is particularly preferred in a form such that it is easily dispersed in a liquid such as water before drinking. Suitably the composition is provided in a particulate or granular solid form, for example as a powder or flakes, intended to be mixed with water, prior
30 to ingestion by a user. Alternatively the composition may be provided as a capsule for dispersal in a liquid, for drinking by a user. Preferably the composition is provided in a particulate form.

In accordance with a second aspect of the present invention there is provided a method of making an ingestible composition comprising a fibre or saccharide 5 bulking agent, an ingestible silica, and an ingestible surfactant, the method comprising the step of blending the fibre or saccharide bulking agent with the ingestible silica and the ingestible surfactant.

10 Preferably no isopropyl alcohol is used in the manufacture.

More preferably no solvent of any type is used in the manufacture.

15 Preferably no polyvinyl pyrrolidone is used in the manufacture.

More preferably no granulating agent of any type is used 20 in the manufacture.

The fibre or saccharide bulking agent may be milled prior to the blending step, suitably to a mean particle size in the range 250-450 μ m.

25 Preferably the method does not include the granulation of the bulking agent.

30 The fibre or saccharide bulking agent may be subjected to a sterilization step prior to the blending step. Irradiation may employ steam or, preferably, a radioactive source, for example a γ -radiation source, for example from

a Cobalt-60 or Caesium-137 source. A suitable radiation dosage is up to 13 kGy, preferably 5-10 kGy.

5 The invention will now be described by way of example in which the following materials are used throughout:

10 Ispaghula - Ispaghula husk material obtained from *Plantago ovata*, broken down to enable the seed kernels to be removed. The material was dried, irradiated with γ -radiation from a Caesium-137 source at a dosage rate of about 7 kGy, as described in PCT/GB01/02040, and milled to a mean particle size of 300-400 μ m.

15 CAB-O-SIL (Trade Mark) - A colloidal silica having a specific surface area in the range 175-225 m^2g^{-1} manufactured by Cabot Inc, USA.

TWEEN 60 (Trade Mark) - A polyoxyethylene sorbitan fatty acid ester, manufactured by ICI.

20 TWEEN 80 (Trade Mark) - A polyoxyethylene sorbitan fatty acid ester, manufactured by ICI.

Propylene glycol.

25 Cremophore RH40 - Glycerol polyethylene glycol oxysterate, manufactured by BASF.

Pricerine - Porcine glycerine, supplied by Uniquema.

30 PEG 200 - Polyethylene glycol, molecular weight approximately 200, manufactured by Clariant.

Liquid surfactants were added slowly to the ispaghula as it was being mixed in a domestic-style MAGIMIXER (Trade Mark). Mixing was continued until the ispaghula appeared evenly covered (dampened).

5

Solid surfactants were ground in a pestle and mortar and then added to the ispaghula and placed in an oven (60-70°C) for 30 minutes. The samples were then quickly blended in the MAGIMIXER as above.

10

To the ispaghula blended with surfactant as described above was added a colloidal silica sample (CAB-O-SIL) in an attempt to dust the samples dry and improve flow characteristics (but also - as will be seen - with the 15 unexpected result that the wetting characteristics of the final product were greatly improved).

No granulation step took place; no granulating agent was used.

Test methods**1. Wettability (dispersion in water)**

5

This was the most important test used to assess the effectiveness of each treatment and simply involved slowly spreading an amount of the formulation containing 3.5g ispaghula onto the surface of 150ml of cold tap water 10 contained in a 200ml Pyrex beaker, and recording the time taken for all the material to become fully wetted without using any agitation to quicken the process.

2. Water absorbency/swell volume

15

This test determines the swell volume (ml) or ability of a product to take up water. This is a key property for the mechanism of action of ispaghula, and hence disruption/reduction to this effect would certainly impact 20 on efficiency.

The method is as follows:

Add 1g of ispaghula (or the equivalent wt of product 25 containing 1g ispaghula) to 100ml of tap water in a 100ml measuring cylinder, mix thoroughly by shaking and allow to stand. At 1 and 2 hours mix again by gentle inversion, and allow to stand for a further 2 hours. At the end of this period (4 hours from start), record the level of 30 mucilage/gel in the measuring cylinder. Typically, this will be 40-50ml per gramme of ispaghula.

3. Gel/flow rate on hydration

This method is used to gain an insight into the rate of gel/mucilage formation. Although gelling is an important 5 attribute, the initial onset has been delayed in ingestible ispaghula compositions to allow the consumer to ingest it, over a period of a few minutes, as a palatable drink.

10 A weight of sample containing 3.5g ispaghula is mixed into 150ml cold tap water in a 200ml beaker. At 5 minute intervals after making up, the time taken for 100ml of the sample to run through a Flow Cup (No. 5) viscometer is recorded. This is basically a brass cup which holds 15 exactly 100ml, with a tapered bottom leading to a standard-sized hole. As a sample gels, then the time taken for 100ml to flow through increases.

4. Carr's Index

20 Carr's index is a measurement of bulk density of pharmaceutical powders, measured in a Copley Erweka Tapped Volumeter, model SVM-22. Powder is placed in a vertical cylinder which is "tapped" in the machine to aid the 25 settlement of the powder, and the percentage change in volume measured, over the predetermined test period/regime, identical for each sample.

Example 1

30 In this series of tests the wetting ability of ternary ispaghula + PEG 200 + CAB-O-SIL compositions was assessed, and compared with non-ternary compositions. The

wettability was measured after 5 minutes, 16-24 hours and 8 days; there is reason from work on other compositions to believe that wettability can decrease as the interval from manufacture increases.

5

As will be seen, there were three replicates. All three results are given in Tables 1-3 below.

10 In each test the measurement was of time (secs) for a dose of treated ispaghula (3.5g) to disperse.

Tables 1-3

PEG 200 + CAB-O-SIL 5 mins after manufacture

15

PEG 200 levels (wt%)	CAB-O-SIL levels (wt%)	
	0.3	0.5
0.4	5,5,5	7,5,6
0.8	7,8,7	6,5,5
1.2	6,4,4	6,7,7

Comparisons: no PEG 200, no CAB-O-SIL: 270, 310, 330
no PEG 200, 0.3 wt% CAB-O-SIL: 165, 170, 165
0.4 wt% PEG 200, no CAB-O-SIL: 120, 130, 135

PEG 200 + CAB-O-SIL 16-24 hours after manufacture

CAB-O-SIL levels (wt%)		
PEG 200 levels (wt%)	0.3	0.5
0.4	6,6,6	7,5,7
0.8	20,20,20	6,5,6
1.2	11,12,11	12,11,12

5 Comparisons: no PEG 200, no CAB-O-SIL: not measured
 no PEG 200, 0.3 wt% CAB-O-SIL: 330, 330, 350
 0.4 wt% PEG 200, no CAB-O-SIL: 305, 320, 320

PEG 200 + CAB-O-SIL 8 days after manufacture

10

CAB-O-SIL levels (wt%)		
PEG 200 levels (wt%)	0.3	0.5
0.4	11,12,11	10,6,7
0.8	25,25,30	8,8,8
1.2	22,30,26	15,17,15

Comparisons: no PEG 200, no CAB-O-SIL: 310, 300, 280
 no PEG 200, 0.3 wt% CAB-O-SIL: 1800, 1200,
 1740
 0.4 wt% PEG 200, no CAB-O-SIL : 470, 480, 510

15

Example 2

This series of tests were as Example 1, but used TWEEN 80
 20 instead of PEG 200, and different time intervals. In

these tests ispaghula alone was not tested. The results are given in Tables 4-6 below. Again, in each test the measurement was of time (secs) for a dose of treated ispaghula (3.5g) to disperse (n=3).

5

Tables 4-6

TWEEN 80 + CAB-O-SIL 5 mins after manufacture

CAB-O-SIL levels (wt%)		
TWEEN 80 levels (wt%)	0.3	0.5
0.09	21, 16, 17	20, 17, 20
0.14	7, 7, 8	8, 5, 8
0.20	4, 4, 5	4, 4, 4

10

Comparisons: no TWEEN 80, no CAB-O-SIL: not measured
 no TWEEN 80, 0.3 wt% CAB-O-SIL: 180, 215, 225
 0.09wt% TWEEN 80, no CAB-O-SIL : 75, 80, 75

15 **TWEEN 80 + CAB-O-SIL 72 hours after manufacture**

CAB-O-SIL levels (wt%)		
TWEEN 80 levels (wt%)	0.3	0.5
0.09	25, 25, 30	30, 22, 25
0.14	10, 13, 11	10, 10, 9
0.20	6, 5, 4	4, 5, 5

20

Comparisons: no TWEEN 80, no CAB-O-SIL: not measured
 no TWEEN 80, 0.3 wt% CAB-O-SIL: 495, 450, 480
 0.09wt% TWEEN 80, no CAB-O-SIL : 63, 70, 60

TWEEN 80 + CAB-O-SIL 7 days after manufacture

CAB-O-SIL levels (wt%)		
TWEEN 80 levels (wt%)	0.3	0.5
0.09	36,27,32	35,35,35
0.14	10,10,12	10,9,8
0.20	7,7,6	4,5,5

5 Comparisons: no TWEEN 80, no CAB-O-SIL: not measured
 no TWEEN 80, 0.3 wt% CAB-O-SIL: 735, 795, 930
 0.09wt% TWEEN 80, no CAB-O-SIL : 75, 67, 78

Again the results for the ternary system are remarkable,
 10 much better than either binary system.

Example 3

This test was used primarily to assess long term
 15 wettability properties. Obviously such properties are
 extremely important for a commercial product.

As before, each experiment employed 3.5g of ispaghula in
 the composition, except that for the swell volume test 1g
 20 of composition was used.

The compositions were placed in a cycling oven, cycling
 between 4°C and 30°C. The samples were tested immediately
 on preparation, after 5 weeks incubation in the cycling
 25 oven, and after 3 months incubation the cycling oven. As
 an exception, compositions including CAB-O-SIL and PEG 200

were tested immediately and after 9 weeks incubation only.
The results of the experiment are shown in Table 7.

Table 7

Storage conditions - Cycling oven (4 °C/30 °C)

The results show that the addition of all of the tested combinations of ingestible silica in combination with an ingestible surfactant, substantially reduces the time taken for the ispaghula to disperse in a 150ml beaker of 5 cold water (wettability). The wettability time is significantly reduced on initial testing and remains reduced through the 5 week samples and the 3 month samples.

10 In particular, polyethylene glycol and TWEEN in combination with CAB-O-SIL show a marked ability to reduce the wettability time of untreated ispaghula husk compared to other combinations of surfactant with CAB-O-SIL. The results therefore indicate that ingestible compositions 15 comprising surfactant plus CAB-O-SIL mixed with ispaghula husk are also shelf stable at ambient temperatures (between 4°C and 30°C) over a sustained period of time.

Example 4

20 The tests corresponded to those of Example 3 but the compositions were tested by incubating at 40°C in an incubating oven. The samples were tested immediately on preparation, after 5 weeks incubation and after 3 months 25 incubation. As an exception, compositions containing CAB-O-SIL and PEG 200 were tested immediately and after 9 weeks incubation only. The results of the experiment are shown in Table 8.

Table 8
Storage conditions: 40°C

Composition	Initial samples				5 week samples				3 month samples			
	Carrs Index (n=2)	Swell Vol (ml) (n=2)	Wettability times (secs)	Flow cup after 15 min (secs)	Swell Vol (ml) (n=2)	Wettability times (secs)	Flow cup after 15 min (secs)	Swell Vol (ml) (n=2)	Wettability times (secs)	Flow cup after 15 min (secs)	Swell Vol (ml) (n=2)	Wettability times (secs)
Untreated Ispaghula		270										
+ 0.16wt% TWEEN 80 + 0.08wt% CAB-O-SIL	9	40	23	45	44	20	18	46	17	40		
+ 0.16wt% TWEEN 60 + 0.08wt% CAB-O-SIL	9	40	20	25	44	22	21	50	16	31		
+ 0.4wt% propylene glycol + 0.08wt% CAB-O-SIL	6	40	44	25	42	85	23	47	110	28		
+ 1.2wt% Cremophore + 0.24wt% CAB-O-SIL	7	40	25	25	41	20	45	37	26	30		
+ 0.4wt% Pricerine + 0.4wt% CAB-O-SIL	7	41.5	50	35	43	180	35	50	364	41		
+ 0.56wt% PEG 200 + 0.24wt% CAB-O-SIL	9	41	15	35				47	26	23		
												<u>9 weeks storage</u>

5

Example 5

10 The wettability testing was repeated for a composition containing barley fibre as the bulking agent, Tween 80 and CAB-O-SIL. The samples were tested immediately on preparation. The results of the experiment are shown in Table 9.

15 Table 9 - Wetting times of Barley Fibre and Tween 80 / CAB-O-SIL Mixtures.

<u>Barley Fibre</u> (g)	<u>Tween 80</u> (mg)	<u>Cabosil</u> (mg)	<u>Wetting</u> <u>Time</u> (seconds)
3.5	0	0	>600
3.5	0	200	280
3.5	0	400	200
3.5	30	0	129
3.5	30	200	102
3.5	30	400	81
3.5	60	0	77
3.5	60	200	56
3.5	60	400	55
3.5	100	0	30
3.5	100	200	24
3.5	100	400	22

20 The results show that for a given amount of Tween, addition of CAB-O-SIL to the composition significantly improves wettability of barley fibre.

5 Example 6

The wettability testing was repeated for a composition containing green pea fibre as the bulking agent, Tween 80 and CAB-O-SIL. The samples were tested immediately on preparation. The results of the experiment are shown in Table 10.

Table 10 - Wetting times of Green Pea Fibre and Tween 80 / CABO-O-SIL Mixtures.

15

<u>Green Pea Fibre (g)</u>	<u>Tween 80 (mg)</u>	<u>Cabosil (mg)</u>	<u>Wetting Time (seconds)</u>
14.2	30	0	42
14.2	60	0	18
14	30	50	12
14	30	100	8
14	0	50	30
14	0	100	13

The results show that for a given amount of Tween, addition of CAB-O-SIL to the composition significantly improves the wettability of pea fibre.

20

25

5 Example 7

The wettability of sodium alginate as the bulking agent was tested. 0.5g of each sample was sprinkled over water and the time taken to wet was recorded.

10

Sodium Alginate (g)	<u>Tween</u> (g)	<u>Colloidal silica</u> (g)	<u>Wetting Time</u> (seconds)
1	-	-	25
0.97	-	0.03	20
0.952	0.04	0.008	15

(Table 11 shows the amounts of each component in a 1g sample. 0.5g of sample was used for each test).

15 The results show that the addition of Tween and colloidal silica significantly reduces wetting time. The reduction in wetting time is not only seen when compared with a sample of untreated sodium alginate but is also seen when compared with a sample containing sodium alginate and 20 colloidal silica. When Tween is added, significantly less colloidal silica is required to result in a significant reduction in the wetting time of the alginate.

5 Claims

1. An ingestible composition comprising a fibre or saccharide bulking agent, an ingestible silica, and an ingestible surfactant wherein said composition is in a form so that in use it is dispersed in a liquid prior to 10 ingestion.
2. An ingestible composition according to claim 1 wherein said composition is in particulate or granular form.
- 15 3. An ingestible composition as claimed in claim 1 or 2 wherein the fibre bulking agent is ispaghula.
4. An ingestible composition as claimed in claim 1 or 2 20 wherein the bulking agent is a polysaccharide-containing bulking agent comprising an algin.
5. An ingestible composition according to claim 1 or 2 25 wherein the fibre bulking agent is cellulose or a derivative thereof.
6. An ingestible composition comprising a fibre bulking agent selected from ispaghula or a bran, an ingestible silica, and an ingestible surfactant.
- 30 7. An ingestible composition according to claim 6 wherein the fibre bulking agent is ispaghula.
8. An ingestible composition as claimed in any preceding 35 claim wherein the particle size of the silica is between 5nm and 5 μ m.

5 9. An ingestible composition as claimed in any preceding
claim wherein the specific surface area of the silica is
between 50 and 400gm⁻².

10 10. An ingestible composition as claimed in any preceding
claim wherein the silica is present in an amount of
between 0.01wt% and 5wt% of the total weight of the
ingestible composition.

15 11. An ingestible composition as claimed in any preceding
claim, wherein the ingestible surfactant is a
polyethylene-, polypropylene-, or polyoxyethylene-based
surfactant.

20 12. An ingestible composition as claimed in claim 11
wherein the polyethylene-based surfactant is a
polyethylene glycol.

25 13. An ingestible composition as claimed in claim 12
wherein the polyethylene glycol has a molecular weight of
between 200 and 40,000, preferably between 200 and 1,000.

14. An ingestible composition as claimed in claim 11
wherein the polyoxyethylene-based surfactant is a
polyoxyethylene sorbitan fatty acid ester.

30 15. An ingestible composition as claimed in claim 11,
wherein the surfactant is a polyoxyethylene monostearate
or a glycerol polyethylene glycol oxystearate.

35 16. An ingestible composition as claimed in any preceding
claim wherein the ingestible surfactant is present in an

5 amount of between 0.01wt% and 5wt% of the total weight of the ingestible composition.

17. An ingestible composition as claimed in claim 16 wherein the ingestible surfactant is polyethylene glycol 10 and is present in an amount of between 0.1wt% and 2wt% of the total weight of the ingestible composition.

18. An ingestible composition as claimed in claim 16 wherein the surfactant is a polyoxyethylene sorbitan fatty 15 acid ester and is present in an amount of between 1wt% and 2wt% of the total weight of the ingestible composition. 19.

19. A method of making an ingestible composition comprising a fibre or saccharide bulking agent, an 20 ingestible silica, and an ingestible surfactant, the method comprising the step of blending the fibre or saccharide bulking agent with the ingestible silica and the ingestible surfactant; preferably without the employment of isopropyl alcohol or more preferably of any 25 solvent; and preferably without the employment of polyvinyl pyrrolidone or more preferably of any granulating agent.

20. An ingestible composition or its manufacture 30 substantially as described herein.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/03040

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A23L1/29 A23L1/308 A61K9/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A23L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 80 00658 A (GRIMBERG G ;BLANIE J (FR); CHANCOGNE P (FR)) 17 April 1980 (1980-04-17) page 1, line 1-15; claims 1,4-7,11,12,16,17; example 2 ---	1-20
X	EP 0 583 852 A (TOKYO TANABE CO) 23 February 1994 (1994-02-23) claims 7,9 page 2, line 24-29,38-50 page 3, line 19-29 ---	1-20
X	EP 0 317 659 A (PRODUCT RESOURCES INT) 31 May 1989 (1989-05-31) claims 1-4; example 2 page 2, line 4-27 page 3, line 21-26,44,45,51,52,56,57 ---	1-20 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

28 October 2003

Date of mailing of the International search report

04/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Tallgren, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/03040

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 214 349 B1 (SEGELMAN ALVIN BURTON) 10 April 2001 (2001-04-10) claim 1; example 2 column 1, line 36-49, 63-67 column 2, line 43-55 column 3, line 23, 43 -column 4, line 15 _____	1-3, 6, 7, 10, 19, 20
A	EP 0 368 534 A (DOW CORNING) 16 May 1990 (1990-05-16) column 3, line 9-27; example 8 _____	9
A	US 5 370 892 A (EL-NOKALY MAGDA ET AL) 6 December 1994 (1994-12-06) column 6, line 22-40 _____	8, 9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/03040

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 8000658	A	17-04-1980	FR	2438431 A1		09-05-1980
			BE	880431 A1		04-06-1980
			EP	0020432 A1		07-01-1981
			WO	8000658 A1		17-04-1980
			GR	73061 A1		27-01-1984
			PT	70286 A		01-11-1979
EP 0583852	A	23-02-1994	JP	1791237 C		29-09-1993
			JP	2053466 A		22-02-1990
			JP	5000031 B		05-01-1993
			JP	1776793 C		28-07-1993
			JP	2053467 A		22-02-1990
			JP	4064666 B		15-10-1992
			JP	1696807 C		28-09-1992
			JP	2079950 A		20-03-1990
			JP	3067662 B		23-10-1991
			EP	0583852 A1		23-02-1994
			AU	619332 B2		23-01-1992
			AU	3992089 A		22-02-1990
			CA	1340159 C		08-12-1998
			DE	68922801 D1		29-06-1995
			DE	68922801 T2		07-12-1995
			DE	68928846 D1		10-12-1998
			DE	68928846 T2		02-06-1999
			EP	0356175 A2		28-02-1990
			KR	151138 B1		15-09-1998
			US	5013576 A		07-05-1991
EP 0317659	A	31-05-1989	US	4731246 A		15-03-1988
			AU	602929 B2		01-11-1990
			AU	8017287 A		27-04-1989
			EP	0317659 A1		31-05-1989
			US	4814172 A		21-03-1989
US 6214349	B1	10-04-2001		NONE		
EP 0368534	A	16-05-1990	US	4925692 A		15-05-1990
			AU	629591 B2		08-10-1992
			AU	4441389 A		10-05-1990
			CA	2000784 A1		07-05-1990
			DE	68911487 D1		27-01-1994
			DE	68911487 T2		23-06-1994
			EP	0368534 A2		16-05-1990
			JP	2219541 A		03-09-1990
US 5370892	A	06-12-1994	CA	2116670 A1		05-03-1993
			DE	69212836 D1		19-09-1996
			DE	69212836 T2		20-02-1997
			EP	0602156 A1		22-06-1994
			JP	6510204 T		17-11-1994
			WO	9304599 A1		18-03-1993